The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aducanumab (1) binds to 3-7 amino acids of Aβ, targeting soluble oligomers and insoluble fibrils.418,419”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [418]
In the citing paper
“Aducanumab has been tested in a phase II study, demonstrating its biological effect in terms of Aβ removal via PET with amyloid tracer [56].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [56]
In the citing paper
“Additionally, amyloid was cleared from the six cortical regions of interest, namely the frontal, parietal, lateral temporal, sensorimotor, anterior, and posterior cingulate areas [43].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Studies have shown that amyloid deposition was reduced in all treatment groups at 26 weeks and further reduced by the end of the first year.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Anti-Aβ immunotherapies have shown reductions in amyloid PET and several amyloid reducing therapies for AD use amyloid PET (or CSF) as a key endpoint [172, 173].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [173]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 901–1,000 of 1,043
Nanoliposomes as a Therapeutic Tool for Alzheimer’s Disease
Ordóñez‐Gutiérrez, L., & Wandosell, F. G. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00020 · Cited by 42
Wang, L., Liu, S., Xu, J., Watanabe, N., Mayo, K. H., Li, J., & Li, X. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15156 · Cited by 41
Madrasi, K. J., Das, R., Abdul, H. M., Lin, L., Hyman, B. T., Lauffenburger, D. A., Albers, M. W., Rissman, R. A., Burke, J. M., Apgar, J. F., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12312 · Cited by 44
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 45
“PRIME enrolled mild or prodromal AD patients with number of adverse events as primary outcome.”
BackgroundInfluentialTakata, K., Ginhoux, F., & Shimohama, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114754 · Cited by 45
Focused Ultrasound Mediated Opening of the Blood-Brain Barrier for Neurodegenerative Diseases
Fishman, P. S., & Fischell, J. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.749047 · Cited by 42
Pardridge, W. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114234 · Cited by 44
Wasielewska, J. M., Chaves, J. C. S., Johnston, R. L., Milton, L. A., Hernández, D., Chen, L., Song, J., Lee, W., Leinenga, G., Nisbet, R. M., et al. (2022) · Theranostics · doi:10.7150/thno.72685 · Cited by 41
“therapeutic AD antibodies: an Aducanumab analogue (anti-Aβ antibody, commercially known as AduhelmTM) [34, 35], and RNF5, an anti-Tau antibody, which has recently been shown to be efficient in reducing p-Tau levels in an animal model with Tau pathology [36].”
BackgroundInfluentialAgger, M. P., Danielsen, E. R., Carstensen, M. S., Nguyen, N. M., Horning, M., Henney, M. A., Jensen, C. B. R., Baandrup, A. O., Kjær, T. W., Madsen, K. H., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221238 · Cited by 44
Connexins and pannexins in Alzheimer’s disease
Giaume, C., Sáez, J. C., Song, W., Leybaert, L., & Naus, C. C. G. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.09.006 · Cited by 42
APOE genotype determines cell-type-specific pathological landscape of Alzheimer’s disease
Li, Z., Martens, Y. A., Ren, Y., Jin, Y., Sekiya, H., Doss, S. V., Kouri, N., Castanedes-Casey, M., Christensen, T. A., Miller Nevalainen, L. B., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.02.017 · Cited by 39
Plasma phosphorylated tau181 predicts cognitive and functional decline
Tropea, T. F., Waligórska, T., Xie, S. X., Nasrallah, I. M., Cousins, K. A. Q., Trojanowski, J. Q., Grossman, M., Irwin, D. J., Weintraub, D. A., Lee, E. B., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51695 · Cited by 40
“Clinical trials aimed at slowing progression to dementia have frequently targeted MCI as a prodromal state of AD, often requiring positive amyloid status.(34,35) In this context, adding information from p-tau181 values may offer an even more fine-grained approach to predicting which individuals within an amyloid+ MCI…”
Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease
Moreira, D. A., Santos, S. D., Leiro, V., & Pêgo, A. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041054 · Cited by 42
“cognitive impairment (MCI) patients [51,52,53,54].”
Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
Saetzler, V., Riët, T., Schienke, A., Henschel, P., Freitag, K., Haake, A. F. H., Heppner, F. L., Buitrago‐Molina, L. E., Noyan, F., Jaeckel, E., et al. (2023) · Cells · doi:10.3390/cells12162115 · Cited by 43
“This approach uses a human IgG1 anti-Aβ monoclonal antibody that induces the clearance of insoluble Aβ plaques by binding to these aggregates in a doseand time-dependent manner [6].”
MethodChoe, M. S., Yeo, H. C., Kim, J., Lee, J., Lee, H. J., Kim, H., Baek, K. M., Jung, N., Choi, M., & Lee, M. Y. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03732-1 · Cited by 45
“Although fAD represents a smaller proportion of cases, most recent drug development efforts, including the first FDA-approved drug, Aducanumab, are based on understanding the mechanisms that underlie fAD onset [12].”
BackgroundSchwierz, N., Frost, C. V., Geissler, P. L., & Zacharias, M. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b10189 · Cited by 39
Ottoy, J., Verhaeghe, J. A. J., Niemantsverdriet, E., Wyffels, L., Somers, C., Roeck, E. E. D., Struyfs, H., Soetewey, F., Deleye, S., den Bossche, T. V., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.184481 · Cited by 42
Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook
Vāvere, A. L., & Scott, P. J. H. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.05.001 · Cited by 42
Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target
Wang, Y., Yan, T., Lu, H.-H., Yin, W., Lin, B., Fan, W.-B., Zhang, X., & Fernandez-Funez, P. (2017) · Neurodegenerative Diseases · doi:10.1159/000478741 · Cited by 35
Anti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects
Kozin, S. A., Barykin, E. P., Mitkevich, V. A., & Makarov, A. А. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918090079 · Cited by 40
Shu, Z., Mao, D., Xu, Y., Shao, Y., Pang, P., & Gong, X. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211029551 · Cited by 43
Ophthalmic Biomarkers for Alzheimer’s Disease: A Review
Majeed, A., Marwick, B., Yu, H., Fadavi, H., & Tavakoli, M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.720167 · Cited by 41
“Conversely, another study showed no association between MMSE score, CSF biomarkers and retinal vasculature, and there were no significantly detectable differences between AD patients and controls (den Haan et al., 2019a).”
BackgroundMethodInfluentialTerao, I., Honyashiki, M., & Inoue, T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101709 · Cited by 42
Kumaran, K. R., Yunusa, S., Perimal, E. K., Wahab, H. A., Müller, C. P., & Hassan, Z. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220666 · Cited by 43
Multiple Targets for the Management of Alzheimer’s Disease
Ahmad, S., Akhtar, S., Jamal, Q. M. S., Rizvi, S. M. D., Kamal, M. A., Khan, M. K., & Siddiqui, M. H. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666161003165855 · Cited by 41
The Arc Gene Confers Genetic Susceptibility to Alzheimer’s Disease in Han Chinese
Initiative, A. D. N., Bi, R., Kong, L., Xu, M., Li, G.-D., Zhang, D., Li, T., Fang, Y., Zhang, C., Zhang, B., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0397-6 · Cited by 43
Qiao, Y., Gu, J., Yu, M., Chi, Y., & Ma, Y. (2024) · CNS Drugs · doi:10.1007/s40263-024-01067-2 · Cited by 38
“However, compared with the positive results of the phase Ib trial for aducanumab [24], it shows that the dose of gantenerumab may be too low to obtain substantial clinical benefit.”
Using Alzheimer's disease blood tests to accelerate clinical trial enrollment
Schindler, S. E., Li, Y., Li, M., Despotis, A., Park, E., Vittert, L., Hamilton, B. H., Womack, K. B., Saef, B., Holtzman, D. M., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12754 · Cited by 38
Self-citationLi, X., Han, J., Bujaranipalli, S., He, J., Kim, E. Y., Kim, H. Y., Im, J. H., & Cho, W. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114444 · Cited by 39
Zhang, S.-S., Gao, Z., Feng, L., & Li, M. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s483412 · Cited by 40
“14 Following this, the Phase III Clarity-AD trial of lecanemab reported in January 2023 a 27% decrease in cognitive decline and other functional impairments over a period of 18 months, thereby achieving its primary endpoint.”
BackgroundSelf-citationNanoscale drug formulations for the treatment of Alzheimer's disease progression
Liqin, L., He, H., Du, B., & He, Y. (2025) · RSC Advances · doi:10.1039/d4ra08128e · Cited by 42
Detection of protein oligomers with nanopores
Horne, R. I., Sandler, S. E., Vendruscolo, M., & Keyser, U. F. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00694-7 · Cited by 42
“1d), do not correlate well with patient outcome 18,26–29 .”
When Patient Engagement and Research Ethics Collide: Lessons from a Dementia Forum
Robillard, J. M., & Feng, T. L. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161285 · Cited by 40
Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation
Novak, P., Cehlar, O., Skrabana, R., & Novak, M. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179942 · Cited by 37
Kim, M. S., Yoon, J. H., & Hong, J. M. (2018) · Clinical Neurophysiology · doi:10.1016/j.clinph.2018.05.004 · Cited by 42
“Early differentiation of DLB from AD at MCI stage is crucial for early intervention and prognosis (Bergstrom et al., 2016; Sevigny et al., 2016).”
BackgroundUnsupervised and real-time spike sorting chip for neural signal processing in hippocampal prosthesis
Xu, H., Yan, H., Han, X., Xu, J., Shen, L., & Cheung, R. C. C. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.10.019 · Cited by 39
Liu, W., Dong, X., & Sun, Y. P. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00440 · Cited by 38
A small molecule Nec-1 directly induces amyloid clearance in the brains of aged APP/PS1 mice
Yang, S., Shin, J., Shin, N. N., Hwang, J., Hong, S.-C., Park, K., Lee, J. W., Lee, S., Baek, S., Kim, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40205-5 · Cited by 39
Jurcau, A., & Simion, A. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200303121016 · Cited by 38
Millan, M. J., Dekeyne, A., Gobert, A., Brocco, M., la Cour, C. M., Ortuno, J., Watson, D. J., & Fone, K. C. F. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108099 · Cited by 40
From Small Molecules to Synthesized Polymers: Potential Role in Combating Amyloidogenic Disorders
Ghosh, P., Bera, A., Bhadury, P., & De, P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00104 · Cited by 39
Targeted protein degraders march towards the clinic for neurodegenerative diseases
Kumar, D., & Hassan, M. I. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101616 · Cited by 38
Sebollela, A., Cline, E. N., Popova, I., Luo, K., Sun, X., Ahn, J., Barcelos, M. A., Bezerra, V. N., Lyra e Silva, N. M., Patel, J., et al. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14118 · Cited by 35
“(2017) 142, 934--947 related imaging abnormalities (vasogenic edema and microhemorrhages) (Farlow and Brosch 2013; Goure et al. 2014; Sevigny et al. 2016).”
Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease
Menéndez‐González, M., Padilla-Zambrano, H., Alvarez, G., Capetillo‐Zarate, E., Tomás‐Zapico, C., & Costa, A. D. D. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00100 · Cited by 40
“The main safety issues are amyloid-related imaging abnormalities (Sevigny et al., 2016).”
BackgroundDavtyan, H., Hovakimyan, A., Kiani Shabestari, S., Antonyan, T., Coburn, M. A., Zagorski, K., Chailyan, G., Petrushina, I., Svystun, O., Danhash, E., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0556-2 · Cited by 37
The dense-core plaques of Alzheimer’s disease are granulomas
Lemke, G., & Huang, Y. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20212477 · Cited by 37
Gustavsson, T., Metzendorf, N. G., Wik, E., Roshanbin, S., Julku, U. H., Chourlia, A., Nilsson, P., Andersson, K. G., Laudon, H., Hultqvist, G., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01236-3 · Cited by 38
“Many late clinical trials of both secretase inhibitors and immunotherapy have failed, but two antibodies, aducanumab (Aduhelm) [1] and lecanemab (Leqembi) [2], have been conditionally approved by the American Food and Drug agency (FDA) for treatment of patients with early AD.”
BackgroundPerspective for Molecular Dynamics Simulation Studies of Amyloid-β Aggregates
Okumura, H. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c06051 · Cited by 38
Lee, J., Lee, H., Lee, H. G., Shin, M., Shin, M.-G., Seo, J., Lee, E. J., Park, S. A., & Park, S. (2023) · Nature Communications · doi:10.1038/s41467-023-44319-3 · Cited by 42
A Review of the Current Status of Disease-Modifying Therapies and Prevention of Alzheimer’s Disease
Parums, D. V. (2024) · Medical Science Monitor · doi:10.12659/msm.945091 · Cited by 49
“Aducanumab is a humanized recombinant monoclonal antibody to amyloid b [25].”
BackgroundMethodInfluentialDrug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?
Sequeira, L., Benfeito, S., Fernandes, C., Gaspar, A., Lima, I., Peixoto, J., Alves, C., Machado, C. S., Borges, F., & Chavarria, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060708 · Cited by 43
“…matrix [220,256]. matrix in response to the 𝛥𝛹 ( − 140 to − 160 ), leading to 100-to 500-fold accumulation within the mitochondrial matrix [220,256]. age, and the disease stage of the patients), most known dietary antioxidants display poor bioavailability and are unable to cross the…”
BackgroundInsulin expression in cultured astrocytes and the decrease by amyloid β
Takano, K., Koarashi, K., Kawabe, K., Itakura, M., Nakajima, H., Moriyama, M., & Nakamura, Y. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.10.017 · Cited by 36
Therapeutic strategies for targeting neurodegenerative protein misfolding disorders
Scannevin, R. H. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.018 · Cited by 42
Self-citationGuo, T., Dukart, J., Brendel, M., Rominger, A., Grimmer, T., Yakushev, I. Y., & Initiative, A. D. N. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.013 · Cited by 39
Pradier, L., Blanchard-Brégeon, V., Bohme, A., Debeir, T., Ménager, J., Benoit, P., Barnéoud, P., Taupin, V., Bertrand, P., Dugay, P., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0447-y · Cited by 39
Alzheimer's “Prevention” vs. “Risk Reduction”: Transcending Semantics for Clinical Practice
Hodes, J. F., Oakley, C. I., O’Keefe, J. H., Lu, P., Galvin, J. E., Saif, N., Bellara, S., Rahman, A., Kaufman, Y., Hristov, H., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2018.01179 · Cited by 38
“Several studies have successfully targeted amyloid-β through the administration of drugs or supplemental interventions, including the use of bapineuzumab, solanezumab, gantenerumab, crenezumab, BAN2401, aducanumab, curcumin, and others (23, 25, 29) but have demonstrated variability in meeting primary outcome measures…”
BackgroundMethodRisk Factors for Alzheimer’s Disease: Focus on Stress
Caruso, A., Nicoletti, F., Gaetano, A., & Scaccianoce, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00976 · Cited by 38
Denver, P., D’Adamo, H., Hu, S., Zuo, X., Zhu, C., Okuma, C., Kim, P., Castro, D., Jones, M. R., Leal, C. D. R., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01269 · Cited by 44
“For example, AD subjects with vascular pathology, such as acute or sub-acute micro-hemorrhage or superficial siderosis, may experience more adverse effects with amyloid-clearing drugs such as anti-amyloid vaccination and may therefore be excluded from clinical trials (Sevigny et al., 2016).”
BackgroundBowroju, S. K., Mainali, N., Ayyadevara, S., Penthala, N. R., Krishnamachari, S., Kakraba, S., Reis, R. J. S., & Crooks, P. A. (2020) · Molecules · doi:10.3390/molecules25163610 · Cited by 39
“The deposition of Aβ plays a crucial role in the pathogenesis of AD [12].”
BackgroundDo, T.-M., Capdevila, C., Pradier, L., Blanchard, V., Lopez‐Grancha, M., Schussler, N., Steinmetz, A. C. U., Beninga, J., Boulay, D., Dugay, P., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.014 · Cited by 37
Peli1 impairs microglial Aβ phagocytosis through promoting C/EBPβ degradation
Xu, J., Yu, T., Pietronigro, E. C., Yuan, J., Arioli, J., Pei, Y., Luo, X., Ye, J., Constantin, G., Mao, C., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000837 · Cited by 38
Liu, X., Wang, K., Wei, X., Xie, T., Lv, B., Zhou, Q., & Wang, X. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03227-y · Cited by 41
Zhan, C., Lao, Z., Tang, Y., Qiao, Q., & Wei, G. (2021) · Chemical Communications · doi:10.1039/d1cc00404b · Cited by 37
Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives
Usman, M. B., Bhardwaj, S., Roychoudhury, S., Kumar, D., Alexiou, A. T., Kumar, P., Ambasta, R. K., Prasher, P., Shukla, S. D., Upadhye, V. J., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.52 · Cited by 43
“The analog of aducanumab has been shown to cross the BBB in transgenic mice; dose-dependent reductions in soluble and insoluble Aβ have also been observed in mice (129).”
A geroscience motivated approach to treat Alzheimer’s disease: Senolytics move to clinical trials
Gonzales, M. M., Krishnamurthy, S., Garbarino, V. R., Daeihagh, A. S., Gillispie, G. J., Deep, G., Craft, S., & Orr, M. E. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111589 · Cited by 39
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 41
“This antibody has been shown to be effective in reducing brain Aβ plaques [52].”
BackgroundThe emerging neuroprotective roles of exerkines in Alzheimer’s disease
Rody, T., Amorim, J. A. D., & Felice, F. G. D. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.965190 · Cited by 40
“Classes of antibodies aimed at targeting Aβ were highly warranted in the field (Farlow et al., 2012; Sevigny et al., 2016).”
BackgroundImplications of Microorganisms in Alzheimer’s Disease
Yadav, P., Lee, Y., Panday, H., Kant, S., Bajwa, N., Parashar, R., Jha, S. K., Jha, N. K., Nand, P., Lee, S., et al. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100314 · Cited by 40
“and reduces the Aβ plaques in the brains of transgenic mice [160].”
BackgroundRen, Y., & Qu, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102040 · Cited by 37
Decoding the autoantibody reactome
Jaycox, J. R., Dai, Y., & Ring, A. M. (2024) · Science · doi:10.1126/science.abn1034 · Cited by 37
Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention
Rafii, M. S., & Aisen, P. S. (2019) · CNS Drugs · doi:10.1007/s40263-018-0598-1 · Cited by 36
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
Kang, Y. J., Diep, Y. N., Tran, M., & Cho, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249591 · Cited by 36
Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects
Li, J., Liao, W., Huang, D., Ou, M., Chen, T., Wang, X., Zhao, R., Zhang, L., Mei, L., Liu, J., et al. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215375 · Cited by 38
Self-citationCeci, C., Lacal, P. M., Barbaccia, M. L., Mercuri, N. B., Graziani, G., & Ledonne, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107101 · Cited by 38
Qian, W., Liu, D., Liu, J., Liu, M., Ji, Q., Zhang, B., Yang, Z., Cheng, Y., & Zhou, S. (2024) · Small · doi:10.1002/smll.202408581 · Cited by 43
Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease
Tomita, T. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.01.001 · Cited by 37
Han, Z., Xue, W., Tao, L., & Zhu, F. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13051 · Cited by 37
Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 38
Coughlan, G., Zhukovsky, P., Puthusseryppady, V., Gillings, R., Minihane, A. M., Cameron, D., & Hornberger, M. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.02.007 · Cited by 37
Koike, H., Iguchi, Y., Sahashi, K., & Katsuno, M. (2021) · Molecules · doi:10.3390/molecules26165091 · Cited by 36
“Following intravenous infusion, this antibody can cross the blood–brain barrier and selectively bind to Aβ aggregates [68].”
BackgroundThe Rhesus Macaque as a Translational Model for Neurodegeneration and Alzheimer’s Disease
Stonebarger, G. A., Bimonte‐Nelson, H. A., & Urbanski, H. F. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.734173 · Cited by 44
“This is because Aβ plaques do not reliably correlate with cognitive decline, and this and previous amyloidlowering drugs have failed to consistently slow dementia onset (Nelson et al., 2012; Sevigny et al., 2016).”
BackgroundKloske, C. M., Dugan, A. J., Weekman, E. M., Winder, Z., Patel, E., Nelson, P. T., Fardo, D. W., & Wilcock, D. M. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab085 · Cited by 38
Physiological Considerations for Modeling in vivo Antibody-Target Interactions
Dunlap, T. C., & Cao, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.856961 · Cited by 38
Shafer, A. T., Williams, O. A., Perez, E., An, Y., Landman, B. A., Ferrucci, L., & Resnick, S. M. (2022) · Brain Communications · doi:10.1093/braincomms/fcac051 · Cited by 37
Saeedi, M., & Mehranfar, F. (2022) · Recent Patents on Biotechnology · doi:10.2174/1872208316666220302115901 · Cited by 42
Liu, S., Li, S., Lin, J., Li, J., & Yang, H. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c00287 · Cited by 37
Disturb mitochondrial associated proteostasis: Neurodegeneration and imperfect ageing
Jagtap, Y. A., Kumar, P., Kinger, S., Dubey, A. R., Choudhary, A., Gutti, R. K., Singh, S., Jha, H. C., Poluri, K. M., & Mishra, A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1146564 · Cited by 36
“Moreover, antibodies-based therapeutics for targeted clearance of Aβ were also explored, however recently FDA-approved aducanumab use for AD treatment remains controversial (Sevigny et al., 2016; Tampi et al., 2021).”
BackgroundMantik, K. E. K., Kim, S., Gu, B., Moon, S., Kwak, H., Park, D., & Kang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411450 · Cited by 41
Hadjichrysanthou, C., Ower, A. K., de Wolf, F., Anderson, R. M., & Initiative, F. T. A. D. N. (2018) · PLOS ONE · doi:10.1371/journal.pone.0190615 · Cited by 35
Liu, Z., Zou, Y. F., Zhang, Q., Chen, P., Liu, Y., & Qian, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20082048 · Cited by 36
“An increasing number of experimental and computational studies have reported that Aβ aggregation can be modulated by nanoparticles [12–14], small molecules [15,16], short peptides [17,18], antibodies [19] and metal ions [20].”
BackgroundNonino, F., Minozzi, S., Sambati, L., Del Giovane, C., Baldin, E., Bassi, M. C., De Santis, C., Gonzalez-Lorenzo, M., Vignatelli, L., Filippini, G., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016297 · Cited by 35
Bad news and good news in AD, and how to reconcile them
Knopman, D. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0131-7 · Cited by 37
Sellés, M. C., Fortuna, J. T. S., Cercato, M. C., Santos, L. E., Domett, L., Bitencourt, A. L. B., Carraro, M. F., de Souza, A. S., Janíčková, H., Azevedo, C. V., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.002 · Cited by 37
Understanding the Molecular Mechanisms of Polyphenol Inhibition of Amyloid β Aggregation
Han, Y.-L., Yin, H., Chao, X., Bernards, M. T., He, Y., & Guan, Y. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00586 · Cited by 37
The Alzheimer's Disease Neuroimaging Initiative Clinical Core
Aisen, P. S. S., Donohue, M., Raman, R., Rafii, M. S., Petersen, R. C., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14167 · Cited by 36
New drugs in psychiatry: focus on new pharmacological targets
Caraci, F., Leggio, G. M., Salomone, S., & Drago, F. (2017) · F1000Research · doi:10.12688/f1000research.10233.1 · Cited by 36
Sri, S., Pegasiou, C.-M., Cave, C. A., Hough, K., Wood, N. J., Gómez‐Nicola, D., Deinhardt, K., Bannerman, D. M., Perry, V. H., & Vargas‐Caballero, M. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0670-1 · Cited by 36
Clinical trials of prion disease therapeutics
Forloni, G., Roiter, I., & Tagliavini, F. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.04.019 · Cited by 37
Microglial autophagy in Alzheimer’s disease and Parkinson’s disease
Wang, Z., Wang, Q., Li, S., Li, X.-J., Yang, W., & He, D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1065183 · Cited by 35
Pankiewicz, J. E., Baquero-Buitrago, J., Sanchez, S., Lopez-Contreras, J., Kim, J., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0156-1 · Cited by 41
“With the advancement of certain newer anti-Aβ immunotherapies such as Gantanerumab and Aducanumab that appear to lower Aβ plaque load in humans to a greater extent than seen previously [6, 8], it will be interesting to see if the effects of APOE genotype noted here in animal models are also present in humans.”
Background
Metadata
- Authors
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R. M., & Sandrock, A.
- Affiliations
- Biogen (United States) (US)
- Light Chain Bioscience (Switzerland) (CH)
- Butler Hospital (US)
- University of Zurich (CH)
- Corresponding author
- Sandrock, Alfred
- ORCID
- Venue
- Nature
- Published
- 2016-08-31
- Volume
- 537
- Issue
- 7618
- Pages
- 50-56
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2510806376
- Cited by
- 3,059
- References
- 42
- Citations by year
- 2026: 186 · 2025: 340 · 2024: 389 · 2023: 332 · 2022: 416 · 2021: 326 · 2020: 263 · 2019: 231 · 2018: 268 · 2017: 252 · 2016: 52
- FWCI
- 214.30
- Type
- journal article
- Language
- en
- Update notices
- addendum (2017-06-22)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- Biogen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid plaques, anti-amyloid monoclonal antibodies, immunotherapy, amyloid hypothesis, transgenic mouse model, prodromal Alzheimer's disease, clinical deterioration, amyloid-related imaging abnormalities, drug safety and tolerability
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Animals, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Humans, Male, Mice, Transgenic, Middle Aged, Models, Biological, Solubility, Amyloid beta-Peptides, Clinical Trials, Phase III as Topic, Mice, Plaque, Amyloid, Antibodies, Monoclonal, Humanized, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.